‘Pfizergan’ deal talks draw tax inversion opposition from Clinton, Trump

Carly Helfand

Pfizer and Allergan–which both confirmed on Thursday that they're in "friendly" –may be intrigued with the prospect of a tie-up. But politicians gung-ho about stopping tax inversions? Not so much.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS